Efficacy and side effect profile of two CMV prophylaxis strategies in high and intermediate risk kidney transplant recipients – a multicentre national study
- 16 November 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 34 (6) , 2173-2175
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-AnalysisJournal of Pharmacy & Pharmaceutical Sciences, 2017
- Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.Clinical Infectious Diseases, 2016
- Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysisClinical Infectious Diseases, 2010
- Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal TransplantationAmerican Journal of Transplantation, 2008
- Cytomegalovirus Prophylaxis and Graft Outcome in Solid Organ Transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2004